Gastric cancer

Raúl is a 67-year-old patient, who came to us in May 2017 with a diagnosis of advanced esophageal cancer, with multiple metastases and a prognosis of 6 months of life. In the time he has been in treatment, the disease has been reduced and therefore his life expectancy has improved.

Case summary:

We share the case of a 67-year-old patient who came to us in May 2017, with a diagnosis of advanced esophageal cancer with metastases in multiple locations.

When we received the medical documentation, we were able to verify that Raúl had stage IV esophageal cancer, specifically a solid and semi-papillary adenocarcinoma of the lower third, obstructive and poorly differentiated, with retroperitoneal and retrocrural, subcarinal and paraesophageal lymph node metastases and multiple pulmonary nodules, predominantly right. He had a prognosis of 6 months to live.

Once the case was analyzed by our specialists, we informed the family what they could expect with Escozul^™ and the possibilities of achieving good results. In such an advanced case, the chances of obtaining good results are not the best.

Each dose of Escozul^™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results that are observed in the patient. For this, effective communication between the patient and our medical team is necessary to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us then the results with Escozul^™ will not be as expected.

Raúl began treatment with Escozul^™ , was receiving radiotherapy and pending to receive chemotherapy.

Evolution, Monitoring and Current Results:

Despite receiving chemotherapy, Raúl's blood parameters have been mostly fine without representing a compromise to health status.

In the PET / CT performed on August 30, 2017, a partial regression of the esophageal tumor was described with a reduction in size almost by half, a decrease in the size of the retroperitoneal and retrocrural lymph node involvement, and pseudoprogression (false progression) of the lung lesions. a predominance of the right side. Subcarinal and paraesophageal lymph node involvement does not appear on this exam.

This, despite the short time of treatment, is a very positive result that implies a change in the life expectancy initially given to the patient, being that Raúl is stable and with a better perspective of evolution.

As we always say, it is important to note that it is not possible to generalize any results with Escozul^™ to avoid creating false expectations in people, Escozul^™ does not work miracles. Only joint work and constant communication make it possible to maintain personalized and functional doses of Escozul^™ against tumors.

It is also important to say that all the medical information of the case is available to be consulted, as well as the contact with the medical counterpart of both the oncologist who treated the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul^™ Protocol, you should know the following: Escozul^™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, or be it can not be sold. Each case that wishes to enter our protocol must be evaluated and approved as Escozul^™ is not effective in all types of tumors. Once approved, the patient and their family members must commit to maintaining fluid contact with our medical team.

To enter the protocol, you must send us an email to: servicios@lifescozulcuba.com indicating the age of the patient, the type of cancer and the physical and emotional state of the patient. This is the first step, and a specialist will take care of the case. Our response time is an hour or two, as each case is answered in a personal, non-automatic way. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by the LifEscozul ^™ Group November / 2017

Medical Documents

Miguel is a 55-year-old patient who was diagnosed with stage IV gastric cancer in early January 2017. The life prognosis according to the doctors in charge of the case in his country was 8 to 12 months. He came to us looking for an alternative treatment that could help him change this prognosis and have a better quality of life.

Case summary:

Today we share the case of a 55-year-old patient who came to us in January 2017, with a diagnosis of stage IV gastric cancer with a prognosis of 8 to 12 months of survival. Although it takes very little treatment, the results so far have been encouraging.

When we received the medical documentation, we were able to verify that Miguel had been diagnosed with stage IV gastric cancer, presenting gastric parietal thickening of the body and antrum, with signs of peritoneal carcinomatosis, and right internal mammary adenopathy.

In terms of symptoms, she had an upset stomach that increased with the consumption of solid foods.

Once the case has been analyzed by our specialists, we inform the patient what to expect with Escozul^™ and the possibilities of achieving good results.

Each dose of Escozul^™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results that are observed in the patient. For this, effective communication between the patient and our medical team is necessary to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us then the results with Escozul^™ will not be as expected.

Miguel began treatment with Escozul^™ in early February 2017. He was pending to start chemotherapy.

Evolution, Monitoring and Current Results:

Although Miguel has been in treatment for a very short time, the results obtained at the moment are very positive.

Three months after starting treatment, in the first control PET CT performed, the following was observed: the thickening of the gastric wall decreased from 14 mm in January to 8 mm in May, the signs of peritoneal carcinomatosis decreased and the Right internal mammary adenopathy from 7.8mm in January to 6.1mm in May.

At this time Miguel continues in treatment with Escozul^™ with increasing doses, seeking to improve the results obtained and help him change his life prognosis.

In this case, it has been achieved, in conjunction with chemotherapy, to help reduce the size of tumor lesions, both mainly at the stomach level, as well as metastases, which opens a door of hope in Miguel's treatment, which began with a prognosis. life limited.

As we always say, it is important to note that it is not possible to generalize any results with Escozul^™ to avoid creating false expectations in people, Escozul^™ does not work miracles. Only joint work and constant communication make it possible to maintain personalized and functional doses of Escozul^™ against tumors.

It is also important to say that all the medical information of the case is available to be consulted, as well as the contact with the medical counterpart of both the oncologist who treated the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul^™ Protocol, you should know the following: Escozul^™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, or be it can not be sold. Each case that wishes to enter our protocol must be evaluated and approved as Escozul^™ is not effective in all types of tumors. Once approved, the patient and their family members must commit to maintaining fluid contact with our medical team.

To enter the protocol, you must send us an email to: servicios@lifescozulcuba.com indicating the age of the patient, the type of cancer and the physical and emotional state of the patient. This is the first step, and a specialist will take care of the case. Our response time is an hour or two, as each case is answered in a personal, non-automatic way. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by the LifEscozul ^™ Group July / 2017

Medical Documents

AB is a 72-year-old patient, who came to us in late July 2016, with a diagnosis of operated gastric cancer, which had metastasized one year after surgery.

Let's start with the description of the case:

The case we share today is about a 72-year-old patient who came to us in July 2016, with a diagnosis of gastric cancer who had undergone surgery in January 2016. Despite the fact that the post-surgery prospects had been good , a year later AB presented numerous metastases in the peritoneum with accumulation of fluid in the pelvic abdominal cavity.

When we received the medical documentation, we were able to verify that it was a primary stomach cancer operated on in 2016. Six months after surgery and three months after the completion of chemotherapy, the July 2016 tomography showed peritoneal carcinomatous tumors determined by tumor nodules in the peritoneum. parietal, and the presence of ascites (free fluid in the abominal pelvic cavity), with the presence of left latero-aortic lymphadenopathy of 20mm and interaortocaval of 14mm. AB indicated a survival time of 6 to 12 months.

Once the case has been analyzed by our specialists, we inform the patient about what to expect with Escozul^™ and the possibilities of achieving good results.

Each dose of Escozul^™ is personalized, specific to the type of tumor and its aggressiveness. These doses can change over time according to the results that are observed in the patient. For this, effective communication between the patient and our medical team is necessary to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us then the results with Escozul^™ will not be as expected.

AB began treatment with Escozul^™ in early August 2016. He was pending to start chemotherapy again.

Evolution, Monitoring and Current Results:

We received the first follow-up AB imaging exams after 6 months of treatment with Escozul^™ , which is the period when results on tumor lesions usually begin to be seen (from 3 to 6 months). According to the description of his relatives, AB had been physically well and in good spirits.

The result of the CT scan performed at the end of January, almost 6 months after starting Escozul^™ , showed that the nodules in the parietal peritoneum and ascites disappeared, meaning that there were no peritoneal carcinomatous tumors. Smaller retroperitoneal adenopathies persisted, the largest being 16mm (previously 20mm).

In 6 months of treatment, it had been possible to reduce the disease, that AB maintained a good quality of life despite chemotherapy and with this give the patient a greater hope of survival.

By August 2017, 1 year after starting the treatment, we received blood tests that are OK, and we were also updated on the patient's symptoms: his physical condition is good, the stomach has not swollen contrary to what predicted by the doctors in his country, his weight is 72 kilos, he gets up very early and does all his work by himself, he feeds several times a day because he always has an appetite, his digestion is good, he does gardening work, and keeps well and active.

At this time, we have already exceeded BA's prognosis for life, which was originally 6 to 12 months, and he has a good quality of life and no signs of deterioration.

We continue the treatment with Escozul^™ with the intention of maintaining and improving the results obtained, to help AB to continue fighting with the disease and having a life as normal as possible.

As we always say, it is important to note that it is not possible to generalize any results with Escozul^™ to avoid creating false expectations in people, Escozul^™ does not work miracles. Only joint work and constant communication make it possible to maintain personalized and functional doses of Escozul^™ against tumors.

It is also important to say that all the medical information of the case is available to be consulted, as well as the contact with the medical counterpart of both the oncologist who treated the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Escozul^™ Protocol, you should know the following: Escozul^™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, or be it can not be sold. Each case that wishes to enter our protocol must be evaluated and approved as Escozul^™ is not effective in all types of tumors. Once approved, the patient and their family members must commit to maintaining fluid contact with our medical team.

To enter the protocol, you must send us an email to: servicios@lifescozulcuba.com indicating the age of the patient, the type of cancer and the physical and emotional state of the patient. This is the first step, and a specialist will take care of the case. Our response time is an hour or two, as each case is answered in a personal, non-automatic way. The idea is that the communication we establish is always governed by a professional and humane treatment.

Prepared by the LifEscozul ^™ Group March / 2017, updated in November 2017

Medical Documents

Let's start with the description of the case:

Susana is a 61-year-old patient, diagnosed in May 2015 with a tumor in the small intestine that was removed by surgery. He contacted us in September 2016, looking for an alternative treatment option that would give him better chances of quality survival.

Upon receiving Susana's medical documentation, we were able to confirm that the initial diagnosis was infiltrating carcinoid of the small intestine (ileum), that one year and 2 months after surgery it had metastasized to the liver, with at least 3 tumor lesions, the largest of which was 17mm in diameter. according to a tomography of July 2016.

Once the case was analyzed by our specialists, we informed the patient about what to expect with Escozul^™ and the possibilities of achieving good results.

Each dose of Escozul^™ is personalized, specifying the type of tumor and its aggressiveness. These doses can change over time according to the results that are observed in the patient. For this, effective communication between the patient and our medical team is necessary to allow us to make the appropriate recommendations on different aspects. If the patient or family members do not maintain fluid communication with us then the results with Escozul^™ will not be as expected.

Susana began treatment with Escozul^™ at the end of September 2016. She was not undergoing any other treatment, she was only under surveillance.

Results and evolution:

During the time of treatment, Susana has been in frequent contact with our team of specialists updating us on her condition and sending the control blood tests.

At the end of February, we received the report of the last tomography performed on Susana, where it is described that there is no change in the number or size of the lesions described in the July 2016 tomography. This means that Susana's disease has kept stable, without presenting any progress.

Although we always want and hope that the disease will be reduced, in most cases, during the first months of treatment with Escozul^™ , it is more common to reduce the growth rate or keep the disease stable. For a cancer patient, it is a good result, since the disease does not progress, there is no impact on their quality of life and their chances of survival improve.

The dose increase has continued according to the Escozul^™ treatment protocol , hoping to help this result to be maintained over time and improve in future reviews.

As we always say, it is important to note that it is not possible to generalize any results with Escozul^™ to avoid creating false expectations in people, Escozul^™ does not work miracles. Only joint work and constant communication make it possible to maintain personalized and functional doses of Escozul^™ against tumors.

It is also important to say that all the medical information of the case is available to be consulted, as well as the contact with the medical counterpart of both the oncologist who treated the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be treated under the Protocol with Escozul ^{™ you} should know the following: Escozul^™ is a product that we are still investigating, including its other properties such as analgesic and anti-inflammatory, therefore it is not a commercial product, or be it can not be sold. Each case that wishes to enter our protocol must be evaluated and approved as Escozul^™ is not effective in all types of tumors. Once approved, the patient and their family members must commit to maintaining fluid contact with our medical team.

To enter the protocol, you must send us an email to:  servicios@lifescozulcuba.com  indicating the age of the patient, the type of cancer and the physical and emotional state of the patient. This is the first step, and a specialist will take care of the case. Our response time is an hour or two, as each case is answered in a personal, non-automatic way. The idea is that the communication that we establish is always governed by a professional and humane treatment.

Prepared by the LifEscozul ^™ Group March / 2017

Medical Documents

Initial diagnostic:

Adenocarcinoma of the Váter ampulla, locally advanced, recurrent after surgery, infiltration of peri-pancreatic vascular structures and duodenum. CA19-9 = 54 (normal limit up to 35). Pleural injury.

Condition of the patient before starting treatment:

- Considerable weight loss

Treatments received:

Palliative chemotherapy was indicated to try to improve his quality of life

Analysis of the case to determine dose and concentration of Escozul^™ .

The case is evaluated by analyzing the type of cancer, its stage, its aggressiveness, applied treatments and response. The physical and psychological condition of the patient is also taken into account.

A copy of this evaluation is sent for the knowledge of the patient and their families.

It begins with Escozul^™ in May 2014, with a prescribed dose according to the progression of the disease. The dose has been increased every 3 months, in search of maintaining and improving results.

The Escozul^™ has the ability to selectively kill cancer cells without affecting healthy cells, leading to control tumor growth and even shrinking tumors, as well as help improve the quality of life of the patient. It works in many types of cancer, with better results in solid tumors, the effectiveness depends on the type of cancer and the degree of advancement of the disease. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717326/

Actual Results:

In January 2015, after 8 months of treatment, these are the main results.

1. General good physical condition

2. Tumor marker value CA19-9 = 10, within normal limits.

3. Pleural lesion and peri-pancreatic involvement disappeared, the rest remain stable.

Currently the patient continues to consume Escozul^™ , with dose restructuring at least every three months.

Resume:

During the treatment period, regression of the cancer has been achieved, improving the physical condition of the patient, reducing tumor markers and keeping them within normal ranges.

It is considered a positive result, since the disease has been reduced and the symptoms eliminated, which leads to an improvement in the patient's quality of life and an increase in their life expectancy. It should be noted that the contact between the patient and our medical team had a decisive influence on achieving these results, since it allowed us to make adjustments to the dose, which in turn had an impact on the disease.

Medical Documents

Initial diagnostic:

Stage IV gastric AC, infiltrating the pancreas, with involvement of the main arterial and venous visceral trunks, metastases to the liver, lungs, peritoneal carcinomatosis, adenopathic mediastinal and hilar involvement with carcinomatous lymphangitis, metastases to the left laterocervical nodes. Bone metastasis.

Condition of the patient before starting treatment:

1. Abdominal pain

2. Anorexia

3. Weight loss

4. General weakness

5. Depression

Treatments received:

Various chemotherapy regimens have been carried out in search of positive results.

Analysis of the case to determine dose and concentration of Escozul^™ .

The case is evaluated by analyzing the type of cancer, its stage, its aggressiveness, applied treatments and response. The physical and psychological condition of the patient is also taken into account.

A copy of this evaluation is sent for the knowledge of the patient and their families.

Start with Escozul^™ in March 2014, according to the advanced disease, it is decided to monitor monthly both with blood tests and tumor markers and liver function tests and the dose is adjusted at least every one month in order to achieve the results expected in the evaluation of the case.

The Escozul^™ has the ability to selectively kill cancer cells without affecting healthy cells, leading to control tumor growth and even shrinking tumors, as well as help improve the quality of life of the patient. It works in many types of cancer, with better results in solid tumors, the effectiveness depends on the type of cancer and the degree of advancement of the disease. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717326/

Actual Results:

In December 2014, after 9 months of treatment, these are the main results:

1. No affectations are observed in the liver or lungs

2. Many of the lymph node metastases have disappeared

3. The primary gastric tumor has decreased in thickness.

4. The life expectancy of the patient has increased.

At the bone level, the disease has not yet been controlled, so it continues with doses in May

Medical Documents

Initial diagnostic:

Initial Diagnosis: Gastric cancer (well differentiated intramucosal adenocarcinoma in lesser curvature of the stomach).

Initial symptoms:

- Elevated carcinoembryonic antigen

Treatments:

She started with Escozul^™ in February 2015. Due to the age and by personal decision of the patient and her relatives, the patient refused surgery and any other treatment option such as chemo and radiotherapy, deciding to treat herself only with Escozul^™ and follow a diet healthy.

It is important to remember that Escozul^™ is a natural product that has the ability to kill tumor cells, without this meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is carried out seeking that the patient can live with their disease with the least possible impact on their daily routine.

Evolution and current results:

As the patient has renounced any conventional treatment, the follow-up of the case so far has been done by monitoring the physical condition of the patient and carrying out blood tests every 3 months.

The tests have shown a decrease in carcinoembryonic antigen, with values close to normal since July 2015, down to 1.7 (in the normal range) in October 2015. All the patient's blood tests are normal.

He has not presented any symptoms, he has maintained a good appetite, he has not lost weight. The patient's condition is good and there is no evidence, either in physical or blood tests, of the advancement of the disease.

Despite not having comparative imaging tests that allow us to establish with certainty the current condition of the disease, the absence of symptoms that reflect disease progression and the decrease in the tumor marker are indicators that the disease is under control.

It has been achieved, with the exclusive use of Escozul^™ and a healthy diet, that the patient maintains a good quality of life, and can carry out daily activities with her family, without presenting any symptoms of the disease

It is important to note that it is not possible to generalize any results with Escozul^™ to avoid creating false expectations in people. Each case we receive is analyzed seeking to inform the family what to expect from it. Each person is a completely different universe from another even if they have the same disease. This writing does not constitute a testimony but a summary of evolution where medical information is available to consult.

Initial diagnostic:

Localized gastric AC, CA125 = 34.2

Initial symptoms:

Loss of appetite

- Weightloss

Treatments received:

She started Escozul^™ in March 2014. The patient refused surgical treatment proposed by the doctors. The patient did not undergo chemotherapy or radiotherapy.

The Escozul^™ is a natural product that has the ability to kill tumor cells without this meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is carried out seeking that the patient can live with their disease with the least possible impact on their daily routine.

Results:

In CT of the chest, abdomen and pelvis, after 3 months in uninterrupted treatment with Escozul^™ , stable disease is observed, without the appearance of new lesions or extension of the disease.

Since the month of treatment she had regained her appetite and the family describes her with great energy and encouragement. The patient has regained 10 kg of weight, and continues to do her daily activities in a normal way, without showing signs of the disease, without affecting her activities and physical and mental well-being.

Another notable result is that the CA125 antigen fell from 34.2 initially to 10.4. Continue consuming Escozul^™ with progressive doses in order to maintain these results.

Actual Results:

In CT of the chest, abdomen and pelvis, after 3 months in uninterrupted treatment with Escozul^™ , stable disease was observed, without the appearance of new lesions or extension of the disease.

Since the first month of treatment, her appetite had recovered and the family reported that Luzmira was feeling very energetic and spirited.

By June 2015, the patient had regained 10 kg of weight, and was continuing to do her daily activities in a normal way, without showing signs of the
disease, without affecting her activities and physical and mental well-being. Also at this time, the CA125 antigen had initially dropped from 34.2 to 10.4.

In October 2015 we received a new update on Luzmira's health: according to her daughter, she was physically well, maintaining a
healthy diet . She also told us that, seeing the patient's conditions, her oncologist recommended that she continue taking Escozul^™ , the only antitumor treatment that Luzmira has.

In the December 2015 exams, the CA125 remained at 10 (normal value). The rest of the blood tests were in normal ranges. The patient continued to show no symptoms of illness.

In May 2016 Luzmira's daughter wrote us again, saying that her mother was still in excellent condition and that her oncologist found her very well. All blood tests were normal.

In August 2016, the blood tests continued normal, and Luzmira's daughter reported that her mother led a totally normal life, without showing any symptoms of the disease.

Luzmira has not undergone other imaging tests, so they can be invasive for gastric cancer follow-up. Although we do not have these results, it can be seen through Luzmira's excellent physical condition and normal blood tests that there is no evidence of disease progression in the 2 years and 5 months that Luzmira has been on treatment with Escozul alone. ^™ . Luzmira continues to consume Escozul^™ with progressive doses in order to maintain these results.

Medical Documents

Initial diagnostic:

Gastric AC II (Borrmann I), with a 7cm mameloned lesion in the greater curvature of the stomach. Forecast of one year of life in May 2014.

Initial symptoms:

• - Weightloss
• - acidity
• - Abdominal pain
• - Reflux
• - vomiting
• - Flatulence
• - Stitches

Treatments received:

He had initially received chemo and radiotherapy, without obtaining good results. She started with Escozul^™ in September 2014. Currently, she has been in treatment with Escozul^™ only for 9 months .

The Escozul^™ is a natural product that has the ability to kill tumor cells without this meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is carried out seeking that the patient can live with their disease with the least possible impact on their daily routine.

Actual Results:

In the last chest-abdomen-pelvis CT, although a slight increase in wall thickness was observed in the body and gastric antrum, the anterior mamelon lesion no longer appeared. His quality of life has also improved remarkably to almost normal levels to the point that he carries out his daily routines without impediments, he has regained weight and many of his initial symptoms no longer appear.

Currently, he continues to consume Escozul^™ with progressive doses in order to maintain these results.

Medical Documents

Case Summary:

Alicia began her treatment with Escozul^™ in 2014, at the age of 54, through her brother who took care of all the necessary steps so that she could start using Escozul^™ and have one more alternative to combat her disease.

As always, the first step was the analysis of the documentation and information provided by the relatives, from which it was obtained that Alicia had cancer in the gastric antrum (well differentiated adenocarcinoma) that infiltrated the duodenum, transmural fat, omentum and hepatoduodenal ligament, associated with ascites. The values of the tumor markers CA125 and CA19-9 were high.

His symptoms initially described were: loss of appetite, nausea, anxiety that interrupted night sleep, early satiety, abdominal distension and nausea.

He started with Escozul^™ in mid-September 2014, with a schedule of progressive dose increases that allowed for positive results, according to the Escozul^™ work protocol . Alicia was undergoing chemotherapy.

It is important to say that Escozul^™ is a natural product which has been shown to kill tumor cells, without this meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is carried out seeking that the patient can live with their disease with the least possible impact on their daily routine.

Evolution and current results:

A month and a half after starting the treatment, although the symptoms of the disease remained, the tumor markers were at normal values.

In December 2014, the family sent a CT report showing a reduction in the size of the gastric lesion and infiltration to the omentum. No change in other injuries.

In January after these results, the patient could undergo a partial gastrectomy, where the tumor mass was removed in the stomach.

Unfortunately during the recovery process, the patient was discovered a Krukenberg tumor (ovarian cancer), which was causing the discomfort in the patient not to decrease. Faced with this situation, the dose of Escozul^™ was drastically increased , seeking to control this new tumor. After 2 months it could also be removed in surgery.

By September 2015, her symptoms had improved a lot and she was evolving favorably.

In October 2015, an ultrasound was performed, which showed no carcinogenic activity at any level, or accumulation of ascites fluid. We must consider that, although this is not a sufficiently precise method for the diagnosis of cancerous lesions, the result itself was taken as very positive.

A new abdominal and pelvic CT scan performed in April 2016, 1 year and 7 months after starting Escozul ^™, showed that the examination is within normal limits, with no evidence of cancerous lesions anywhere. Alicia has gained weight and does not report discomfort, other than a certain limitation with eating due to the reduction in the size of the stomach.

In a case as advanced as Alicia's, and with the complications that she presented during the treatment, having a "clean" CT scan at this time is a very important result, considering also that a recovery of her quality of life and their chances and survival time have certainly increased considerably.

As we always say, it is important to point out that it is not possible to generalize any results with Escozul^™ to avoid creating false expectations in people, Escozul^™ does not work miracles. Only joint work and constant communication make it possible to maintain personalized and functional doses of Escozul^™ against tumors.

It is also important to say that all the medical information of the case is available to be consulted, as well as the contact with the medical counterpart of both the oncologist who treated the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

If you wish to be assisted by our specialists, please contact us at: servicios@lifescozulcuba.com. If you want to know about Escozul^™ and our work, visit us on our website: www.escozul-cuba.com.

Prepared by the LifEscozul ^™ Group

Medical Documents

Initial diagnostic:

Esophageal cancer (poorly differentiated, infiltrating intestinal-type adenocarcinoma), with metastases to surrounding and retroperitoneal nodes. Presence of ascites. Prognosis of around 8 months of life.

Initial symptoms:

- Difficulty feeding due to the presence of a tumor.

Treatment:

He started Escozul^™ in February 2015. The patient was undergoing chemotherapy treatment, with negative effects on post-chemotherapy blood parameters. It is important to remember that Escozul^™ is a natural product that has the ability to kill tumor cells, without this meaning that it is a cure for cancer. Its ability to inhibit malignant cell growth allows it to be used as a disease controller and the work approach is carried out seeking that the patient can live with their disease with the least possible impact on their daily routine.

Evolution and current results:

Once the treatment with Escozul ^{™ began} , the patient improved his diet, as his appetite increased, and he managed to better withstand chemotherapy, with less damage to blood parameters. His physical condition has remained stable despite the prognosis and the presence of the tumor, making it difficult to eat.

In September CT of the chest and abdomen, it is observed that the primary tumor is stable, the lymph nodes have reduced in size, and the ascites has disappeared.

seven months after starting treatment, the patient remains stable, even with a decrease in secondary affectations, which certainly extends his life prognosis, in addition to the fact that Escozul^™ has helped him to improve the side effects of chemotherapy and to feel better physically. In an advanced case, these are significant achievements that represent a significant benefit to the patient.

It is important to note that it is not possible to generalize any results with Escozul^™ to avoid creating false expectations in people. Each case we receive is analyzed seeking to inform the family what to expect from it. Each person is a completely different universe from another even if they have the same disease. This writing does not constitute a testimony but a summary of evolution where medical information is available to consult.

Medical Documents

Initial diagnostic:

Non-operable gastric cancer and node metastasis. The stomach wall widened by about 3 cm, the main cause of pain when eating.

Condition of the patient before starting treatment:

1. He had abdominal pain, he ate in small quantities because feeding was painful.

2. Difficulty sleeping.

3. Vomiting.

Treatment received:

Chemotherapies. Later rejected by the doctors because the results were not as expected.

Analysis of the case to determine dose and concentration of Escozul^™ .

The case is evaluated by analyzing the type of cancer, its stage, its aggressiveness, applied treatments and response. The physical and psychological condition of the patient is also taken into account.

A copy of this evaluation is sent for the knowledge of the patient and their families. She starts with Escozul^™ in May 2014, a high dose is prescribed, according to the progression of the disease and the patient's symptoms.

The Escozul^™ has the ability to selectively kill cancer cells without affecting healthy cells, leading to control tumor growth and even shrinking tumors, as well as help improve the quality of life of the patient. It works in many types of cancer, with better results in solid tumors, the effectiveness depends on the type of cancer and the degree of advancement of the disease. http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3717326/

Actual Results:

In November 2014, after 6 months of treatment, these are the main results:

1. The tumor has decreased markedly and the thickening of the walls decreased to 0.8cm, from 3cm which it was initially.

2. The patient can eat normally.

3. You have returned to all your daily activities including driving.

4. During the chemotherapy cycles, she had no noticeable side effects. Currently the doctors have suspended chemotherapy and recommended that he continue with the alternative treatment because, in their opinion, it is working better.

After the last analyzes carried out, we received the latest report from the patient's family that we transcribed verbatim: "I am very pleased to communicate with you to congratulate you for giving us this option to fight a disease as deadly as cancer. Today I inform you that my father was officially declared cancer free. This has been news that has filled our family and friends with happiness. We will be the spokesperson for the benefits of your product, we will make known to those who need it and we will recommend your company. On behalf of our family and especially my father, we thank you with all our heart".

Resume

The results obtained agree with what was observed in other similar cases. It is worth highlighting the constancy in the control of the side effects produced by chemotherapy. Currently the patient continues with a recovery plan based on concentrated doses of Escozul^™ .

The result is considered positive, since it has been possible to reduce the size of the tumor and eliminate secondary locations, which leads to an improvement in the quality of life of the patient and extending the life span.

Medical Documents

Initial diagnostic:

Stage IV, metastatic cancer of the duodenum operated on

How it started with Escozul^™ :

It came to us through his son, who like so many relatives of patients was looking for another treatment option for his father that would help him improve life expectancy and physical condition.

Our team received the medical documents of the case where we could observe that it was a previously operated cancer in the duodenum, with metastases in the tail of the pancreas and lymph nodes in the precardiac area.

Treatment received:

Regarding physical symptoms, Max reported:

• - Intermittent abdominal pain
• - Difficulty to sleep
• - Decay
• - Pain in feet and hands

Analysis of the case and start with Escozul^™ .

As always, we inform the family about these results and the possibilities of responding to treatment with Escozul^™ . With the approval of the patient to carry out the treatment, we proceed to prepare the dose, designed in order to obtain the best possible results according to the case, both in terms of combating the disease and improving the quality of life.

Max began treatment with Escozul^™ in August 2015, in conjunction with chemotherapy treatment.

Actual Results:

Max has been on Escozul^™ for a year now. He remains in good physical condition despite chemotherapy, with mild symptoms.

In a new tomography performed at the end of April 2016, no lymph node involvement was observed, nor was the lesion in the pancreas observed.
In any type of stage IV cancer, doctors talk about palliative care, to extend the life span. The fact of achieving the reduction or elimination of lesions is very important and leads to an increase in life expectancy and the life span of the patient. It also reverts to an improvement in the quality of life, reducing or eliminating symptoms such as difficulties sleeping, anxiety, which are mainly associated with the emotional state of insecurity and fear that people with such an advanced cancer diagnosis present. Max's results have been exceptional and also reflect his perseverance and commitment to treatment.

Resume

As we always say, it is important to note that it is not possible to generalize any results with Escozul^™ to avoid creating false expectations in people, Escozul^™ does not work miracles. Only joint work and constant communication make it possible to maintain personalized and functional doses of Escozul^™ against tumors.

It is also important to say that all the medical information of the case is available to be consulted, as well as the contact with the medical counterpart of both the oncologist who treated the case and our specialists. We believe in transparency in dealing with our patients and the right to form an opinion based on information and analysis.

Medical Documents